Unknown

Dataset Information

0

Direct effects of exendin-(9,39) and GLP-1-(9,36)amide on insulin action, ?-cell function, and glucose metabolism in nondiabetic subjects.


ABSTRACT: Exendin-(9,39) is a competitive antagonist of glucagon-like peptide-1 (GLP-1) at its receptor. However, it is unclear if it has direct and unique effects of its own. We tested the hypothesis that exendin-(9,39) and GLP-1-(9,36)amide have direct effects on hormone secretion and ?-cell function as well as glucose metabolism in healthy subjects. Glucose containing [3-(3)H]glucose was infused to mimic the systemic appearance of glucose after a meal. Saline, GLP-1-(9,36)amide, or exendin-(9,39) at 30 pmol/kg/min (Ex 30) or 300 pmol/kg/min (Ex 300) were infused in random order on separate days. Integrated glucose concentrations were slightly but significantly increased by exendin-(9,39) (365 ± 43 vs. 383 ± 35 vs. 492 ± 49 vs. 337 ± 50 mmol per 6 h, saline, Ex 30, Ex 300, and GLP-1-[9,36]amide, respectively; P = 0.05). Insulin secretion did not differ among groups. However, insulin action was lowered by exendin-(9,39) (25 ± 4 vs. 20 ± 4 vs. 18 ± 3 vs. 21 ± 4 10(-4) dL/kg[min per ?U/mL]; P = 0.02), resulting in a lower disposition index (DI) during exendin-(9,39) infusion (1,118 ± 118 vs. 816 ± 83 vs. 725 ± 127 vs. 955 ± 166 10(-14) dL/kg/min(2) per pmol/L; P = 0.003). Endogenous glucose production and glucose disappearance did not differ significantly among groups. We conclude that exendin-(9,39), but not GLP-1-(9,36)amide, decreases insulin action and DI in healthy humans.

SUBMITTER: Sathananthan M 

PROVIDER: S-EPMC3717878 | biostudies-literature | 2013 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Direct effects of exendin-(9,39) and GLP-1-(9,36)amide on insulin action, β-cell function, and glucose metabolism in nondiabetic subjects.

Sathananthan Matheni M   Farrugia Luca P LP   Miles John M JM   Piccinini Francesca F   Dalla Man Chiara C   Zinsmeister Alan R AR   Cobelli Claudio C   Rizza Robert A RA   Vella Adrian A  

Diabetes 20130401 8


Exendin-(9,39) is a competitive antagonist of glucagon-like peptide-1 (GLP-1) at its receptor. However, it is unclear if it has direct and unique effects of its own. We tested the hypothesis that exendin-(9,39) and GLP-1-(9,36)amide have direct effects on hormone secretion and β-cell function as well as glucose metabolism in healthy subjects. Glucose containing [3-(3)H]glucose was infused to mimic the systemic appearance of glucose after a meal. Saline, GLP-1-(9,36)amide, or exendin-(9,39) at 30  ...[more]

Similar Datasets

| S-EPMC6316314 | biostudies-literature
| S-EPMC4103924 | biostudies-literature
| S-EPMC2928367 | biostudies-literature
| S-EPMC2671126 | biostudies-literature
| S-EPMC2350427 | biostudies-literature
| S-EPMC6168908 | biostudies-literature
| S-EPMC7104271 | biostudies-literature
| S-EPMC4589823 | biostudies-literature
| S-EPMC5761487 | biostudies-literature
| S-EPMC8281614 | biostudies-literature